Developer docs
API playgroundTry for free, no card

Search company profiles

Perpetual Medicines

Full company profile

uuid0002tcd

Namestring
Perpetual Medicines
Legal namestring
Perpetual Medicines Corporation
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Perpetual Medicines is a fully integrated computational peptide therapeutics company founded in 2023 and domiciled in the United States (Perpetual Medicines Corporation) with operational hubs in Shanghai, China and Boston, Massachusetts. The company is building a next-generation peptide drug discovery engine that combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access unexplored peptide chemical space. Its core product is a single platform that uses AI, deep learning, and physics-based computation to design peptide therapeutics with binding characteristics intended to rival or exceed monoclonal antibodies while being approximately 30 times smaller, enabling superior tissue penetration and intracellular target engagement. The platform also supports constrained structures and unnatural amino acids to produce novel biochemical properties.

The company operates in three therapeutic verticals — oncology (with a specific focus on β-catenin / WNT pathway targets), autoimmune diseases, and metabolic disorders — leveraging peptide modalities to address protein-protein interactions and other targets previously considered undruggable by small molecules or biologics. As a pre-clinical / early clinical stage company, Perpetual Medicines has no commercialized products and no disclosed revenue; its business model is internal pipeline advancement with the stated goal of moving its most advanced program to clinical stages. Its customers are effectively its own R&D programs, with the long-term monetization pathway implying out-licensing, co-development partnerships, or M&A.

Perpetual Medicines is led by a veteran management team: Co-founder, Chairman and CEO Kerry L. Blanchard (PhD, MD), previously CSO at Innovent and a senior R&D leader at Eli Lilly for ~18 years; CSO Xiang Ye (PhD), a 22-year Lilly veteran who led the discovery and development of Verzenio (abemaciclib); and CTO Ved Srivastava (PhD), former Head of Peptide Chemistry at GSK and Amylin who was instrumental in the development of Byetta, Symlin, and Bydureon. The company raised an $8 million seed round in December 2023 led by Chengwei Capital and in 2025 completed a merger with TandemAI, which concurrently closed a $22 million Series A extension, materially expanding its discovery and development footprint into both peptide and small molecule modalities.

Short descriptiontext

Perpetual Medicines is a 2023-founded, US-incorporated computational peptide therapeutics company (Shanghai and Boston) that uses AI, physics-based modeling, and synthetic chemistry to discover peptide drugs for oncology, autoimmune, and metabolic diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational peptide discovery, AI-driven drug design, peptide therapeutics platform, oncology drug discovery, biopharmaceutical research
Industry2 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Computational Peptide Drug Discovery
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Perpetual Medicines is a fully integrated computational peptide therapeutics company developing a next-generation peptide drug discovery engine. The platform combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space and design peptide therapeutics targeting previously undruggable proteins, with an internal pipeline focused on oncology, autoimmune, and metabolic diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • The company aims to move its most advanced program to clinical stages
+1 more record
Product overview1 text field

Perpetual Medicines operates as a fully integrated computational peptide therapeutics company offering a single unified platform that combines computational physics methods and next-generation AI technologies with advanced synthetic chemistry. The platform is designed to access unexplored peptide chemical space, address previously undruggable targets, and accelerate peptide therapeutics development. The company focuses on oncology, autoimmune, and metabolic diseases, with operations in Shanghai, China and Boston, MA.

Product and service1 record
1Computational Peptide Drug Discovery Platform
CategoryDrug Discovery Platform
Description

A next-generation peptide drug discovery engine that combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space, enabling the design of peptide therapeutics with high specificity and binding characteristics comparable to or better than monoclonal antibodies for previously undruggable targets.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Perpetual Medicines merged with TandemAI, a drug discovery company with an AI-powered platform combining computational methods with wet lab capabilities. TandemAI raised a $22M Series A extension to support growth in small molecule business and its merger with Perpetual Medicines, enhancing the combined drug discovery and development process.

Peers10 records
TypeDirect peer
Description

AI-driven generative biology company designing novel protein therapeutics with machine learning. Closely comparable as a generative-AI protein/peptide design platform pursuing previously undruggable targets — same architectural philosophy as Perpetual's AI + synthetic chemistry stack.

TypeBroad incumbent
Description

Global biopharmaceutical company with a significant biologics and peptide-based portfolio (e.g., osteoporosis, oncology). Comparable as a large incumbent in biologic/peptide therapeutics, though Amgen's business is far broader than Perpetual's discovery-stage platform.

TypeBroad incumbent
Description

AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning. Overlaps with Perpetual on the philosophy of integrating computation and wet-lab experimentation, though Recursion operates at much larger scale and across multiple modalities.

TypeBroad incumbent
Description

Global pharma with leading peptide/incretin franchise and deep peptide R&D heritage (Byetta/Bydureon originated in Lilly research). Comparable on peptide therapeutics and incretin biology, and a likely strategic partner/acquirer — Lilly is also Perpetual CEO Blanchard and CSO Ye's former employer.

TypeDirect peer
Description

Clinical-stage biotech developing bicyclic peptide therapeutics (Bicycles) for oncology and other diseases. Directly comparable as a peptide-engineered modality platform pursuing intracellular and difficult-to-drug targets with differentiated chemistry — overlapping modality and target-class focus with Perpetual.

TypeBroad incumbent
Description

Danish peptide therapeutics company with a track record of approved peptide drugs (e.g., in metabolic disease) and a pipeline spanning rare disease and metabolic indications. Comparable on peptide modality and focus areas including metabolic disease.

TypeEmerging player
Description

Machine-learning driven drug discovery company combining data generation (including induced pluripotent stem cells) with predictive models. Overlaps with Perpetual on the AI/ML drug discovery thesis, though Insitro focuses on small molecules and is more platform-data driven than peptide-chemistry driven.

TypeBroad incumbent
Description

Clinical-stage peptide therapeutics company developing oral and injectable peptides across endocrine and oncology indications. Comparable to Perpetual on the peptide-therapeutics modality and metabolic/oncology focus areas.

9PeptiDream
TypeDirect peer
Description

Japan-based peptide discovery company using a proprietary Peptide Discovery Platform System (PDPS) to identify non-standard peptides against diverse targets. Closely comparable as a discovery-stage peptide platform with multiple pharma partnerships, similar business model to Perpetual's computational peptide engine.

TypeBroad incumbent
Description

Computational drug discovery platform combining physics-based simulation with ML, with both internal pipeline and software/collaboration revenue. Comparable to Perpetual on the physics + AI computational methodology, though Schrödinger's platform is broader (small molecules and biologics) and includes established software business.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Perpetual Medicines

Computational Peptide Drug Discoveryperpetualmeds.com

Perpetual Medicines is a 2023-founded, US-incorporated computational peptide therapeutics company (Shanghai and Boston) that uses AI, physics-based modeling, and synthetic chemistry to discover peptide drugs for oncology, autoimmune, and metabolic diseases.

What Perpetual Medicines does

Perpetual Medicines is a fully integrated computational peptide therapeutics company founded in 2023 and domiciled in the United States (Perpetual Medicines Corporation) with operational hubs in Shanghai, China and Boston, Massachusetts. The company is building a next-generation peptide drug discovery engine that combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access unexplored peptide chemical space. Its core product is a single platform that uses AI, deep learning, and physics-based computation to design peptide therapeutics with binding characteristics intended to rival or exceed monoclonal antibodies while being approximately 30 times smaller, enabling superior tissue penetration and intracellular target engagement. The platform also supports constrained structures and unnatural amino acids to produce novel biochemical properties.

The company operates in three therapeutic verticals — oncology (with a specific focus on β-catenin / WNT pathway targets), autoimmune diseases, and metabolic disorders — leveraging peptide modalities to address protein-protein interactions and other targets previously considered undruggable by small molecules or biologics. As a pre-clinical / early clinical stage company, Perpetual Medicines has no commercialized products and no disclosed revenue; its business model is internal pipeline advancement with the stated goal of moving its most advanced program to clinical stages. Its customers are effectively its own R&D programs, with the long-term monetization pathway implying out-licensing, co-development partnerships, or M&A.

Perpetual Medicines is led by a veteran management team: Co-founder, Chairman and CEO Kerry L. Blanchard (PhD, MD), previously CSO at Innovent and a senior R&D leader at Eli Lilly for ~18 years; CSO Xiang Ye (PhD), a 22-year Lilly veteran who led the discovery and development of Verzenio (abemaciclib); and CTO Ved Srivastava (PhD), former Head of Peptide Chemistry at GSK and Amylin who was instrumental in the development of Byetta, Symlin, and Bydureon. The company raised an $8 million seed round in December 2023 led by Chengwei Capital and in 2025 completed a merger with TandemAI, which concurrently closed a $22 million Series A extension, materially expanding its discovery and development footprint into both peptide and small molecule modalities.

Perpetual Medicines firmographics

Firmographics
Name
Perpetual Medicines
Legal name
Perpetual Medicines Corporation
Website
https://perpetualmeds.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Perpetual Medicines is a 2023-founded, US-incorporated computational peptide therapeutics company (Shanghai and Boston) that uses AI, physics-based modeling, and synthetic chemistry to discover peptide drugs for oncology, autoimmune, and metabolic diseases.
Ownership category
akta.pro rank

Perpetual Medicines industry classification

Industry
Product category
Computational Peptide Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Computational peptide discovery
  • AI-driven drug design
  • Peptide therapeutics platform
  • Oncology drug discovery
  • Biopharmaceutical research

Where Perpetual Medicines is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Perpetual Medicines business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Perpetual Medicines product offering

Product offering

Core offering

Perpetual Medicines is a fully integrated computational peptide therapeutics company developing a next-generation peptide drug discovery engine. The platform combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space and design peptide therapeutics targeting previously undruggable proteins, with an internal pipeline focused on oncology, autoimmune, and metabolic diseases.

Product overview

Perpetual Medicines operates as a fully integrated computational peptide therapeutics company offering a single unified platform that combines computational physics methods and next-generation AI technologies with advanced synthetic chemistry. The platform is designed to access unexplored peptide chemical space, address previously undruggable targets, and accelerate peptide therapeutics development. The company focuses on oncology, autoimmune, and metabolic diseases, with operations in Shanghai, China and Boston, MA.

Differentiator

Problem solved

Functional benefit

Products and services

  • Computational Peptide Drug Discovery Platform A next-generation peptide drug discovery engine that combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space, enabling the design of peptide therapeutics with high specificity and binding characteristics comparable to or better than monoclonal antibodies for previously undruggable targets.

Quantifiable outcome

  • The company aims to move its most advanced program to clinical stages
  • +1 more outcomes

Companies that use Perpetual Medicines

Customer profile

Segments3 records

Ideal customer profiles1 record

Perpetual Medicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Perpetual Medicines partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TandemAIcoreStrategic or Co-development Partner · 1 November 2025Perpetual Medicines merged with TandemAI, a drug discovery company with an AI-powered platform combining computational methods with wet lab capabilities. TandemAI raised a $22M Series A extension to support growth in small molecule business and its merger with Perpetual Medicines, enhancing the combined drug discovery and development process.

Scale indicators2 records

Perpetual Medicines competitors and assessment

Company assessment

Direct peers

  • Generate Biomedicines: AI-driven generative biology company designing novel protein therapeutics with machine learning. Closely comparable as a generative-AI protein/peptide design platform pursuing previously undruggable targets — same architectural philosophy as Perpetual's AI + synthetic chemistry stack.
  • Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide therapeutics (Bicycles) for oncology and other diseases. Directly comparable as a peptide-engineered modality platform pursuing intracellular and difficult-to-drug targets with differentiated chemistry — overlapping modality and target-class focus with Perpetual.
  • PeptiDream: Japan-based peptide discovery company using a proprietary Peptide Discovery Platform System (PDPS) to identify non-standard peptides against diverse targets. Closely comparable as a discovery-stage peptide platform with multiple pharma partnerships, similar business model to Perpetual's computational peptide engine.

Broad incumbents

  • Amgen: Global biopharmaceutical company with a significant biologics and peptide-based portfolio (e.g., osteoporosis, oncology). Comparable as a large incumbent in biologic/peptide therapeutics, though Amgen's business is far broader than Perpetual's discovery-stage platform.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning. Overlaps with Perpetual on the philosophy of integrating computation and wet-lab experimentation, though Recursion operates at much larger scale and across multiple modalities.
  • Eli Lilly: Global pharma with leading peptide/incretin franchise and deep peptide R&D heritage (Byetta/Bydureon originated in Lilly research). Comparable on peptide therapeutics and incretin biology, and a likely strategic partner/acquirer — Lilly is also Perpetual CEO Blanchard and CSO Ye's former employer.
  • Zealand Pharma: Danish peptide therapeutics company with a track record of approved peptide drugs (e.g., in metabolic disease) and a pipeline spanning rare disease and metabolic indications. Comparable on peptide modality and focus areas including metabolic disease.
  • Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company developing oral and injectable peptides across endocrine and oncology indications. Comparable to Perpetual on the peptide-therapeutics modality and metabolic/oncology focus areas.
  • Schrödinger: Computational drug discovery platform combining physics-based simulation with ML, with both internal pipeline and software/collaboration revenue. Comparable to Perpetual on the physics + AI computational methodology, though Schrödinger's platform is broader (small molecules and biologics) and includes established software business.

Emerging players

  • Insitro: Machine-learning driven drug discovery company combining data generation (including induced pluripotent stem cells) with predictive models. Overlaps with Perpetual on the AI/ML drug discovery thesis, though Insitro focuses on small molecules and is more platform-data driven than peptide-chemistry driven.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights6 records

Customer concentration

Perpetual Medicines social profiles

Digital presence

Perpetual Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Perpetual Medicines leadership team

Management profile

Number of profiles

Perpetual Medicines funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Perpetual Medicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perpetual Medicines

What does Perpetual Medicines do?

Perpetual Medicines is a fully integrated computational peptide therapeutics company developing a next-generation peptide drug discovery engine. The platform combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space and design peptide therapeutics targeting previously undruggable proteins, with an internal pipeline focused on oncology, autoimmune, and metabolic diseases.

Is Perpetual Medicines a public or private company?

Perpetual Medicines is a private company. It is classified as venture growth investor backed and is currently operating.

When was Perpetual Medicines founded?

Perpetual Medicines was founded in 2023. It employs 1 to 10 people.

Where is Perpetual Medicines based?

Perpetual Medicines is headquartered in Shanghai, China, in the Asia region.

Who are Perpetual Medicines's main competitors?

Direct peers on record are Generate Biomedicines, Bicycle Therapeutics and PeptiDream. Broad incumbents are Amgen, Recursion Pharmaceuticals, Eli Lilly, Zealand Pharma, Crinetics Pharmaceuticals and Schrödinger. Insitro is listed as an emerging player.

Does Perpetual Medicines have an API?

No public API is recorded for Perpetual Medicines.

What industry is Perpetual Medicines in?

Perpetual Medicines's product category is Computational Peptide Drug Discovery. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AI InsiderTandemAI and Perpetual Medicines Announce Strategic Merger to Expand Physics and AI-Based Drug Discovery CapabilitiesTandemAI and Perpetual Medicines merged to form an expanded TandemAI, combining AI, physics-based, and wet-lab drug discovery capabilities. The combined company will integrate Perpetual's peptide design platform as a separate entity, with over 150 drug discovery collaborations and multiple programs nearing clinical trials.YahooTandemAI and Perpetual Medicines Announce Strategic Merger to Expand Physics and AI-Based Drug Discovery CapabilitiesTandemAI and Perpetual Medicines announced a merger, forming a combined company focused on AI and physics-based drug discovery technologies for small molecule and peptide therapeutics. The merger aims to leverage the strengths of both companies in advancing drug discovery and development, with a focus on biopharma collaborations and clinical trials.TandemaiTandemAI And Perpetual Medicines Announce Strategic Merger To Expand Physics And AI-Based Drug Discovery CapabilitiesTandemAI and Perpetual Medicines announced a strategic merger on July 10, 2025, combining their respective AI and physics-based drug discovery platforms under the TandemAI name. The merged company will offer integrated capabilities for both small molecule and peptide-based therapeutics, serving over 150 biopharma partners including biotech firms, pharmaceutical companies, and academic institutions. Perpetual Medicines will operate as a separate entity within TandemAI, with its leadership team including Dr. Kerry L. Blanchard and Dr. Ved Srivastava, while TandemAI co-founder Jeff He will serve as CEO of the combined company.FinSMEsPerpetual Medicines Raises $8M in Seed FundingPerpetual Medicines raised $8M in seed funding led by Chengwei Capital. The funds will advance its computational peptide drug discovery platform, which combines AI and synthetic chemistry. The company also announced key leadership appointments.PedailyThe peptide drug development company 'Dongtai Pharmaceutical' has completed an $8 million seed round financing.Perpetual Medicines has completed an $8 million seed financing round led by Chengwei Capital to advance its computational peptide drug discovery platform. The company, which has offices in Shanghai and Boston, will use the funds to move leading projects into clinical stages and expand its preclinical portfolio in oncology and metabolic diseases.PharmiWeb.comPerpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug DiscoveryPerpetual Medicines has completed an $8 million seed financing round to advance its integrated computational design and synthesis platform for peptide drug discovery. The round was led by Chengwei Capital, and the funding will help the company push its most advanced program into clinical stages while continuing to build its preclinical portfolio in various therapeutic areas. The company aims to leverage AI and new technologies to enhance the peptide drug discovery process, particularly addressing previously undruggable targets.Business Wire BlogPerpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug DiscoveryPerpetual Medicines closed an $8 million seed round led by Chengwei Capital to advance its computational design-synthesis platform for peptide drug discovery. The company will use the funds to advance its most advanced program to clinical stage and build preclinical projects in oncology, autoimmunity, and metabolic diseases.